Evidence map›Paper›PMID 38705793›Full record

ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2024

Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma.

Benjamin J Van Treeck, Maria C Olave, Ryan D Watkins, Haiyan Lu, Roger K Moreira, Taofic Mounajjed, Michael J Johnson, Carin Y Smith, Sumera I Ilyas, Nguyen H Tran and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Benjamin J Van TreeckMayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
Maria C OlaveMayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
Ryan D WatkinsMayo Clinic, Department of Surgery, Department of Biochemistry and Molecular Biology, Rochester, MN, USA.
Haiyan LuCleveland Clinic, Department of Pathology, Cleveland, OH, USA.
Roger K MoreiraMayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
Taofic MounajjedMayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
Michael J JohnsonMayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
Carin Y SmithMayo Clinic, Department of Quantitative Health Sciences, Rochester, MN, USA.
Sumera I IlyasMayo Clinic, Division of Gastroenterology and Hepatology, Department of Immunology, Rochester, MN, USA.
Nguyen H TranMayo Clinic, Department of Oncology, Rochester, MN, USA.
Sarah M JenkinsMayo Clinic, Department of Quantitative Health Sciences, Rochester, MN, USA.
Katelyn A ReedMayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
Rory SmootMayo Clinic, Department of Surgery, Department of Biochemistry and Molecular Biology, Rochester, MN, USA.
Amit MahipalMayo Clinic, Department of Oncology, Rochester, MN, USA; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland OH, USA.
Daniela AllendeCleveland Clinic, Department of Pathology, Cleveland, OH, USA.
Rondell P GrahamMayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA. Electronic address: graham.rondell@mayo.edu.

Funding

Working to Eliminate Care Disparities in Liver Cancer in Southeast Asian Americans: Transportation and Other Social Determinants of Health.K23MD017217 · NIMHD · MAYO CLINIC ROCHESTER · PI Nguyen H Tran · 2022 to 2026
$818k
NIMHD NIH HHS K23 MD017217
6 · The paper itself

Abstract

backgroundIntrahepatic cholangiocarcinoma (iCCA) is the second most common hepatic malignancy and has a poor prognosis. Surgical resection is the standard of care for patients with resectable disease, representing 30-40% of cases. Increasingly, neoadjuvant systemic therapy is being utilized in patients due to high-risk anatomic or biologic considerations. However, data on the clinical effect of this approach are limited. We performed a cohort study to evaluate the effect of neoadjuvant therapy in patients with oncologically high-risk iCCA.

methodsiCCA patients (n = 181) between the years 2014-2020 were reviewed for clinical, histopathologic, treatment, and outcome-related data. Tumor regression grade was scored per CAP criteria for gastrointestinal carcinomas.

results47 iCCA patients received neoadjuvant therapy and 72 did not. Neoadjuvant treatment led to objective response and tumor regression by CAP score. After adjustment for age, clinical stage, and tumor size, the outcomes of patients who had neoadjuvant therapy followed by surgery were not significantly different from those patients who had surgery first. DISCUSSION: In conclusion, neoadjuvant therapy in iCCA facilitated surgical care. The progression-free and overall survival for surgical patients with and without neoadjuvant therapy were not significantly different suggesting this approach needs further exploration as an effective treatment paradigm.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaNeoadjuvant TherapyAgedFemaleHepatectomyHumansMaleMiddle AgedRetrospective StudiesTreatment Outcome

Identifiers

PMID38705793
PMCPMC11504318

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.